NCT00390793View on ClinicalTrials.gov

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

September 28, 2006

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions
Acute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic Leukemiat(9;22)
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV or IT

DRUG

Dasatinib

Given PO

DRUG

Dexamethasone

Given IV or PO

DRUG

Doxorubicin

Given IV

DRUG

Methotrexate

Given IV or IT

DRUG

Prednisone

Given PO

DRUG

Vincristine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00390793 - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | Biotech Hunter | Biotech Hunter